In this cohort study of patients with atrial fibrillation or flutter initiating DOAC treatment, we sought to investigate whether the use of factor Xa inhibitor had an effect on cancer incidence and cancer-related mortality. This evidence concerns the gene F10 and atrial fibrillation.